Xeris Pharmaceuticals (XERS) Is A Stock That RBC Capital Seems to be Very Interested In

July 16, 2018 - By Ash Maslow

Why Has RBC Capital Given Xeris Pharmaceuticals (XERS) a $24.0 Price Target

Investment analysts at RBC Capital has a key “Outperform” rating for Xeris Pharmaceuticals (XERS). The firm has started coverage in analysts report issued to clients and investors on Monday morning. The target price per share would suggest upside of 30.43 % from the current stock price.

The stock decreased 0.54% or $0.1 during the last trading session, reaching $18.4. About 32,485 shares traded. Xeris Pharmaceuticals, Inc. (XERS) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. The company has market cap of $378.87 million. The Company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. It currently has negative earnings. The company's lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes.

More notable recent Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) news were published by: Seekingalpha.com which released: “Stocks To Watch: Prime Time In Retail” on July 14, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on July 16, 2018, Benzinga.com published: “The Week Ahead In Biotech: Conferences, Clinical Trial Results, IPOs And More” on July 14, 2018. More interesting news about Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) were released by: Nasdaq.com and their article: “Xeris Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock” published on June 20, 2018 as well as Streetinsider.com‘s news article titled: “Xeris Pharmaceuticals (XERS) Reports Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use …” with publication date: June 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.